3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
10
Active not recruiting
5
Not yet recruiting
3
Terminated
2
Recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1
Carcinoma
1
Interventions
Cisplatin
22
Carboplatin
15
Radiotherapy
13
Paclitaxel
11
Gemcitabine
10
Rituximab
9
Fluorouracil
9
Drug Therapy
6
Dexamethasone
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
Vinorelbine
4
Pemetrexed
4
Nivolumab
4
Methotrexate
4
Etoposide
4
Docetaxel
4
Bendamustine Hydrochloride
4
spartalizumab
3
pertuzumab
3
pembrolizumab
3
fludarabine
3
Vincristine
3
Trastuzumab
3
Surgical Procedures, Operative
3
Standard of Care
3
Prednisone
3
Oxaliplatin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Withdrawn
×
trifluridine tipiracil drug combination
×
Clear all
NCT03717038
2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3
Withdrawn